FDA’s Latest Nitrosamine Guidance 2026: NDSRI Risk Assessment, Acceptable Intake Limits And Compliance Guide

What the FDA’s July 2026 Nitrosamine Guidance Means for Pharmaceutical Manufacturers, Drug Developers and CDMOs

The U.S. Food and Drug Administration (FDA) continues to strengthen its approach to controlling nitrosamine impurities in pharmaceutical products. On 24 July 2026, the FDA updated its guidance on nitrosamine drug substance-related impurities (NDSRIs), introducing additional active pharmaceutical ingredient (API)-specific entries, including imitative and several dalbavancin-related NDSRIs.

The update builds on the FDA’s ongoing efforts to expand acceptable intake (AI) recommendations and improve the scientific assessment and control of nitrosamine impurities in medicines.

For pharmaceutical manufacturers, generic drug developers, contract development and manufacturing organizations (CDMOs), and marketing authorization holders, the development reinforces the importance of a proactive, science-based nitrosamine risk management strategy throughout the product lifecycle.

Nitrosamine impurities may form during manufacturing, storage, or through interactions between drug substances, excipients, packaging components, and other product constituents. Depending on the compound and exposure level, certain nitrosamines may present potential carcinogenic risks, making effective identification, assessment, and control essential.

Companies supplying medicines to the U.S. market should review their existing risk assessments, manufacturing processes, analytical methods, specifications, and stability data against applicable FDA recommendations.

Why the FDA’s Nitrosamine Guidance Matters

Nitrosamines are chemical compounds that can occur as impurities in pharmaceutical products. Certain nitrosamines have demonstrated carcinogenic potential, and their presence in medicines requires careful scientific evaluation.

Nitrosamine impurities are generally considered in two broad categories:

• Small-molecule nitrosamines: Impurities such as N-nitroso dimethylamine (NDMA) and N-nitrosodiethylamine (NDEA).
• Nitrosamine drug substance-related impurities (NDSRIs): Nitrosamines structurally related to a drug substance, which may form because of the API’s molecular structure and the chemical conditions encountered during manufacturing or storage.

NDSRIs can be particularly challenging because their formation potential and toxicological properties may vary significantly between APIs.

The FDA’s evolving guidance provides recommendations for assessing these risks, establishing acceptable intake limits, and implementing appropriate control strategies.

For pharmaceutical companies, nitrosamine compliance should therefore be integrated into drug development, formulation design, process validation, quality assurance, analytical testing, stability programs, and regulatory submissions.

What Changed in the FDA’s July 2026 Update?

The FDA’s 24 July 2026 guidance update continues the expansion of its nitrosamine impurity recommendations.

Key areas of relevance include:

• Additional API-specific NDSRI entries.
• Updated or expanded acceptable intake recommendations for listed impurities.
• Continued emphasis on scientifically justified impurity limits.
• Greater importance of compound-specific toxicological assessment.
• The need for documented risk assessments and appropriate analytical controls.
• Continued consideration of alternative acceptable intake limits when supported by adequate scientific evidence.

The update identifies mitapivat and several dalbavancin-related NDSRIs among the additional entries described in the supplied announcement.

Companies should consult the current FDA guidance and associated tables to confirm the specific impurity names, applicable AI values, and conditions relevant to each product.

Key Regulatory Considerations

Understanding Nitrosamine Drug Substance-Related Impurities (NDSRIs)

NDSRIs are nitrosamine impurities structurally related to the active pharmaceutical ingredient. Their formation can depend on the presence of susceptible chemical groups, nitrosation agents, process conditions, and other contributing factors.

Potential formation pathways may involve:

• Secondary or tertiary amine-containing APIs or intermediates.
• Nitrite impurities in excipients or other raw materials.
• Nitrosating agents introduced during manufacturing.
• Processing conditions that facilitate nitrosamine formation.
• Interactions between formulation components.
• Storage conditions that influence impurity formation.

Not every API containing an amine group will necessarily form an NDSRI. A product-specific assessment is needed to determine the relevant chemical pathways and the likelihood of impurity formation.

Manufacturers should consider both the potential for nitrosamine formation and the ability of existing controls to prevent, detect, or limit that formation.

Acceptable Intake Limits and Toxicological Assessment

Acceptable intake (AI) limits represent the amount of a particular impurity considered acceptable for daily exposure under the applicable regulatory framework.

The appropriate AI may depend on the impurity’s identity, available toxicological evidence, and the applicable FDA recommendations.

Where an NDSRI is listed in the current FDA guidance, manufacturers should verify the corresponding recommendation and evaluate whether the product’s maximum daily dose and impurity concentration could result in exposure exceeding the applicable limit.

Where an impurity lacks a directly applicable AI recommendation, additional scientific assessment may be necessary.

Depending on the circumstances, this may involve:

• Evaluation of available toxicological data.
• Structure-based assessment and read-across were scientifically appropriate.
• Enhanced Ames testing or other relevant testing strategies.
• Justification of an alternative AI were permitted and supported by evidence.
• Documentation of the rationale, uncertainties, and proposed control strategy.

Alternative AI limits should not be assumed to be acceptable without adequate supporting evidence and consideration of the applicable FDA recommendations.

Which Pharmaceutical Products and Processes May Be Affected?

Nitrosamine risk assessment may be relevant across a broad range of pharmaceutical products and manufacturing activities.

The presence of a potential risk factor does not automatically mean that a product contains nitrosamine impurity. Companies should establish product-specific conclusions using scientific evidence.

FDA Nitrosamine Compliance Requirements: What Companies Should Review

The FDA’s recommendations make it important for companies to maintain a documented, risk-based approach to nitrosamine impurity management.

1. Nitrosamine Risk Assessment

Manufacturers should evaluate the API structure, synthesis route, raw materials, excipients, manufacturing conditions, and potential impurity formation pathways.

Risk assessments should explain the scientific rationale for identifying or excluding relevant risks.

2. Confirmatory Analytical Testing

Where a potential risk is identified, appropriate analytical testing may be required to confirm the presence or absence of the relevant impurity.

Depending on the impurity and product, laboratories may use liquid chromatography–tandem mass spectrometry (LC-MS/MS), high-resolution mass spectrometry (HRMS), or other suitable methods.

Analytical methods should be appropriately developed and validated or qualified for their intended use.

3. Root Cause Investigation

When nitrosamines are detected, companies should investigate the underlying cause rather than relying solely on additional testing.

Investigations may evaluate raw materials, excipients, process chemistry, equipment, manufacturing conditions, packaging, and storage-related formation pathways.

4. Control Strategies and Specifications

Companies should implement controls that address the identified root cause and reduce the risk of unacceptable impurity levels.

Depending on the findings, these may include changes to raw material specifications, supplier qualification, process parameters, formulation components, analytical controls, or finished-product specifications.

5. Stability and Lifecycle Monitoring

Risk management should continue after product approval. Changes in formulation, suppliers, manufacturing processes, or storage conditions may affect nitrosamine formation potential.

Stability data and appropriate ongoing monitoring can help demonstrate that impurity levels remain controlled throughout the product’s life.

Nitrosamine Compliance Readiness Checklist for 2026

Frequently Asked Questions

1. What did the FDA update in July 2026?

The FDA updated its nitrosamine drug substance-related impurities guidance on 24 July 2026, expanding its recommendations with additional API-specific entries, including mitapivat and several dalbavancin-related NDSRIs.

2. What are NDSRIs?

NDSRIs are nitrosamine impurities structurally related to an active pharmaceutical ingredient. They may form during manufacturing or storage when suitable chemical conditions and precursors are present.

3. What is an acceptable intake limit?

An acceptable intake limit is a recommended level of daily exposure to a specific impurity under the applicable regulatory framework. The relevant value should be verified against the current FDA recommendations and supporting scientific evidence.

4. Does the updated guidance affect generic drug manufacturers?

Generic drug manufacturers should assess the update's relevance to their products, manufacturing processes, analytical controls, and regulatory documentation.

5. Is nitrosamine testing required for every pharmaceutical product?

Testing requirements depend on the product-specific risk assessment and applicable regulatory expectations. Companies should determine whether testing is necessary based on credible formation pathways and available evidence.

6. Can companies propose an alternative AI limit?

An alternative AI may be scientifically supportable in appropriate circumstances, subject to applicable FDA recommendations and sufficient evidence, which may include toxicological data or enhanced Ame’s testing. Acceptance should not be assumed.

7. Why is root cause analysis important?

Root cause analysis helps identify the source and mechanism of impurity formation, enabling manufacturers to implement effective preventive controls rather than relying on testing alone.

8. Should existing approved products be reassessed?

Companies should evaluate whether the updated recommendations or new scientific information affect their existing products, prior risk assessments, control strategies, or supporting documentation.

Conclusion

The FDA’s July 2026 nitrosamine guidance update reinforces the importance of proactive, scientifically justified impurity management throughout pharmaceutical development and manufacturing.

The addition of API-specific NDSRI entries and the continued expansion of acceptable intake recommendations highlight the need for companies to maintain current risk assessments, suitable analytical methods, robust manufacturing controls, and appropriate toxicological justifications.

For pharmaceutical manufacturers, generic drug developers, and CDMOs, effective nitrosamine management extends beyond impurity detection. It requires understanding potential formation mechanisms, identifying root causes, implementing preventive measures, and maintaining control throughout the product lifecycle.

Companies should review the latest applicable FDA recommendations, reassess relevant products, strengthen supplier oversight, and ensure that analytical and regulatory documentation supports their compliance decisions.

A proactive approach can help organizations identify potential risks earlier, improve product quality, and support continued compliance with evolving pharmaceutical impurity expectations.

How Maven Regulatory Solutions Can Help

Maven Regulatory Solutions can support pharmaceutical companies with regulatory and quality activities relevant to nitrosamine impurity management, including:

• Nitrosamine regulatory assessments.
• Pharmaceutical impurity risk assessment support.
• NDSRI applicability reviews.
• Regulatory gap assessments.
• Product and formulation risk reviews.
• Supplier documentation assessments.
• Analytical and toxicological data review coordination.
• Manufacturing process and change-control assessments.
• Regulatory documentation support.
• Pharmaceutical lifecycle compliance.
• Regulatory intelligence and guidance monitoring.

Our approach helps manufacturers and product developers identify potential compliance gaps, strengthen risk-based decision-making, and establish practical strategies aligned with evolving pharmaceutical regulatory expectations.